Drugs / parainfluenza virus type 3 vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06604767 | Sep 2024 → Mar 2026 | parainfluenza infectious disease, respiratory syncytial virus infectious disease | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-09-06 | Clover Biopharmaceuticals AUS Pty | Results Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults cloverbiopharma.com ↗
Robust neutralizing antibody responses across RSV, hMPV and PIV3 in Phase 2 recapitulates Phase 1 results demonstrating best-in-class breadth (with no immune interference) and no drop-off in responses in the oldest participants (75+ years) |
| 2025-10-14 | Clover Biopharmaceuticals AUS Pty | Results Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults cloverbiopharma.com ↗
Increases in neutralizing antibodies of approximately 6-8 fold for RSV, 6-9 fold for hMPV and 4 fold for PIV3 (≥10 fold increases in PIV3 PreF-specific antibodies) were observed |
| 2019-10-02 | ModernaTX, Inc. | Results Moderna to Present Data From Two of Its Prophylactic mRNA Vaccines at IDWeek 2019 q4web.com ↗
Phase 1 data show first combination vaccine against respiratory viruses hMPV and PIV3 (mRNA-1653) boosted hMPV and PIV3 neutralizing antibody titers above baseline through seven months; |
| 2019-08-07 | ModernaTX, Inc. | Results Moderna Provides Business Updates and Reports Second Quarter 2019 Financial Results q4web.com ↗
Second planned interim analysis of Phase 1 hMPV and PIV3 vaccine (mRNA-1653) study showed antibody titers remained above baseline at all dose levels at seven months |
| 2019-02-12 | ModernaTX, Inc. | Results Moderna Announces Positive Interim Phase 1 Data for First Combination Vaccine Against the Respiratory Viruses hMPV and PIV3 q4web.com ↗
Interim data show vaccination with mRNA-1653 boosted serum neutralization titers against hMPV and PIV3 at all dose levels tested and was generally well tolerated |
All press releases naming this drug 7 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | parainfluenza virus type 3 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06604767 ↗ |
| Known as | PIV3 | “parainfluenza virus type 3 vaccine (PIV3)” NCT06604767 ↗ |
| Modality | Vaccine | “Parainfluenza Virus Type 3 Vaccine Candidate” NCT06604767 ↗ |
| Route | Intramuscular | “Route of administration:Intramuscular” NCT06604767 ↗ |